Related references
Note: Only part of the references are listed.Antiemetics: ASCO Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients
Yasmeen Razvi et al.
SUPPORTIVE CARE IN CANCER (2019)
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial
Amber B. Clemmons et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis
Leonard Chiu et al.
SUPPORTIVE CARE IN CANCER (2016)
Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting
Rudolph M. Navari et al.
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY (2016)
New therapies for antiemetic prophylaxis for chemotherapy
Mellar P. Davis
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY (2016)
Management of Chemotherapy-Induced Nausea and Vomiting Focus on Newer Agents and New Uses for Older Agents
Rudolph M. Navari
DRUGS (2013)
The current status of the use of palonosetron
Rudolph Navari
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Share Paper
